Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31190804 | 0.85 | CYP4F2 (0.33) | CYP4F2CYP4A11RET | |
| SCHEMBL31361807 | 0.85 | ATR (0.36) | ATRCYP4F2CYP4A11RET | |
| SCHEMBL31190602 | 0.82 | CYP4F2 (0.44) | HTR3AATRCYP4F2CYP4A11CNR2 | |
| SCHEMBL31190796 | 0.81 | P2RX7 (0.38) | CYP4F2CYP4A11RET | |
| SCHEMBL15568853 | 0.81 | CYP4F2 (0.39) | ATRCYP4F2CYP4A11RET | |
| SCHEMBL31190729 | 0.81 | CYP4F2 (0.37) | EGFRHTR3ACYP4F2CYP4A11CNR1 | |
| SCHEMBL31484933 | 0.81 | CYP4F2 (0.39) | ATRCYP4F2CYP4A11RET | |
| SCHEMBL29147744 | 0.80 | CHRM2 (0.34) | ATRCYP4F2CYP4A11RETCRHR1 | |
| SCHEMBL30633955 | 0.80 | CHRM2 (0.34) | ATRCYP4F2CYP4A11RETCRHR1 | |
| SCHEMBL14723265 | 0.80 | RET (0.36) | ATRCYP4F2CYP4A11RETGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-116761798-A | Indazoles as kinase inhibitors | 泰拉生物科学公司 | 2023-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071428-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | EGFR 98/4885BTK 14/4885HTR3A 2418/4885 |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | EGFR 98/4885BTK 14/4885HTR3A 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.